

Resource Summary Report

Generated by [nidm-terms](#) on Jul 28, 2026

amide

RRID:SCR_005940

Type: Tool

Proper Citation

amide (RRID:SCR_005940)

Resource Information

URL: <http://amide.sourceforge.net/index.html>

Proper Citation: amide (RRID:SCR_005940)

Description: Software tool for viewing, analyzing, and registering volumetric medical imaging data sets. It has been written on top of GTK+ and runs on any system that supports this toolkit (Linux, Windows, Mac OS X, etc.). The program incorporates automatic non-orthogonal data reslicing, allowing multiple data set to be fused without imposed constraints on the dimensions, anisotropy, or voxel sizes of the data. Additional features include 3D ROI (ellipses, cylinders, boxes, and isocontours), multi-slice viewing, volume rendering, and data importing through the (X)MedCon library.

Abbreviations: AMIDE

Synonyms: , a medical image data examiner, A Medical Image Data Examiner

Resource Type: software application, image analysis software, software resource, data processing software

Defining Citation: [PMID:14649056](#)

Keywords: volumetric medical imaging data, data analysis, data visualization, non-orthogonal data

Availability: Free, Freely available

Resource Name: amide

Resource ID: SCR_005940

Alternate IDs: nif-0000-00261

Alternate URLs: <https://sources.debian.org/src/amide/>

License: GNU GPL

Record Creation Time: 20220129T080233+0000

Record Last Update: 20260728T043225+0000

Ratings and Alerts

No rating or validation information has been found for amide.

No alerts have been found for amide.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 472 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#).

Ellingson BM, et al. (2025) A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma. *Neuro-oncology advances*, 7(1), vdaf022.

Wang TA, et al. (2025) Neuroprotective potential of isofraxidin: Alleviating parkinsonian symptoms, inflammation and microglial activation. *Journal of central nervous system disease*, 17, 11795735241312661.

Day I, et al. (2025) [18F]FDG-PET and [18F]MPPF-PET are brain biomarkers for the creatine transporter Slc6a8 loss of function mutation. *Scientific reports*, 15(1), 7280.

Dahlén AD, et al. (2025) PET imaging of TREM2 in amyloid-beta induced neuroinflammation. *European journal of nuclear medicine and molecular imaging*, 52(11), 4320.

Meher N, et al. (2025) PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer. *Molecular cancer therapeutics*, 24(1), 141.

He X, et al. (2025) Forebrain neural progenitors effectively integrate into host brain circuits and improve neural function after ischemic stroke. *Nature communications*, 16(1), 5132.

Kethamreddy M, et al. (2025) Evaluation of [18F]F-CNBI and [18F]F-CNPI PET Probes in GSK-3? Transgenic Mice. *ACS chemical neuroscience*, 16(17), 3340.

Ramos-Torres K, et al. (2024) Common anesthetic used in preclinical PET imaging inhibits metabolism of the PET tracer [18F]3F4AP. *Journal of neurochemistry*, 168(9), 2577.

Pandey A, et al. (2024) Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C-MHC I complex Demonstrates the Antitumor Efficacy of Hapten-Based Strategies. *Cancer research*.

Saeedi Saghez B, et al. (2024) First preclinical SPECT/CT imaging and biodistribution of [165Er]ErCl₃ and [165Er]Er-PSMA-617. *EJNMMI radiopharmacy and chemistry*, 9(1), 90.

Pagnon de la Vega M, et al. (2024) Altered amyloid- β structure markedly reduces gliosis in the brain of mice harboring the Uppsala APP deletion. *Acta neuropathologica communications*, 12(1), 22.

Wanek T, et al. (2024) Functionalization of 68Ga-Radiolabeled Nanodiamonds with Octreotide Does Not Improve Tumor-Targeting Capabilities. *Pharmaceuticals (Basel, Switzerland)*, 17(4).

Ye RZ, et al. (2024) Adipocyte hypertrophy associates with in vivo postprandial fatty acid metabolism and adipose single-cell transcriptional dynamics. *iScience*, 27(1), 108692.

Singh R, et al. (2024) Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma. *Frontiers in oncology*, 14, 1432286.

Li Y, et al. (2024) Distinct Urinary Metabolite Signatures Mirror In Vivo Oxidative Stress-Related Radiation Responses in Mice. *Antioxidants (Basel, Switzerland)*, 14(1).

Centonze M, et al. (2024) Development and characterization of DIA 12.3, a fully human intact anti-CEACAM1 monoclonal antibody. *PloS one*, 19(2), e0295345.

Sharma AK, et al. (2024) CD38-Specific Gallium-68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 11(16), e2308617.

Gustavsson T, et al. (2024) Indium-111 radiolabelling of a brain-penetrant A β antibody for SPECT imaging. *Uppsala journal of medical sciences*, 129.

Dadgar M, et al. (2024) Assessing the deep learning based image quality enhancements for the BGO based GE omni legend PET/CT. *EJNMMI physics*, 11(1), 86.

Kim J, et al. (2024) Development, Characterization, and Radiation Dosimetry Studies of 18F-BMS-986229, a 18F-Labeled PD-L1 Macrocyclic Peptide PET Tracer. *Molecular imaging and biology*, 26(2), 301.